Drugs Made In America Acquisition Corp

Research Drugs Made In America Acquisition Corp (DMAA) on Bullrun: market cap USD 261.22M, P/E 57.9. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 261.22M; P/E is 57.9.

Peer valuation comparison

Latest P/E is 57.88x versus a Financial Services sector median of 13.84x (318.3% above).

Latest P/E is 57.88x versus a United States median of 24.87x (132.8% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 0USD 5.94M-USD 539.19Kn/a0.38USD 6.14KUSD 60.90K-USD 7.26M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 261.22M57.9n/an/a
20252025-12-31USD 349.65M57.6n/an/a

About Drugs Made In America Acquisition Corp

Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.

Related stock research

Other Financial Services stocks

Frequently asked questions

What is Drugs Made In America Acquisition Corp's market cap?

Drugs Made In America Acquisition Corp's market capitalization is USD 261.22M.

What is Drugs Made In America Acquisition Corp's P/E ratio?

Drugs Made In America Acquisition Corp's price-to-earnings (P/E) ratio is 57.9.

What does Drugs Made In America Acquisition Corp do?

Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.